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Abstract
Objective: Every Western nation expends vast sums on
health, especially for cancer; thus, the question is how effi-
cient is the UK in reducing adult (55–74) cancer mortality
rates and total mortality rates (TMR) compared to the
other Western nations in the context of economic-input
to health, the percentage of Gross-Domestic-Product-
expenditure-on-Health.
Design: WHO mortality rates for baseline 3 years 1989–
1991 and 2008–2010 were analysed, and confidence inter-
vals determine any significant differences between the UK
and other countries in reducing the mortalities. Efficiency
ratios are calculated by dividing reduced mortality over the
period by the average % of national income.
Setting: Twenty-one similar socio-economic Western
countries.
Participants: The 21 countries’ general population.
Main outcome measures: Cancer mortality rates, total
mortality rates Gross Domestic Product and Efficiency
Ratios.
Results: Economic Input: In 1980, UK national income was
5.6% and the European average was 7.1%. By 2010, UK
national income was 9.4% being equal 17th of 21 averaging
7.1% over the period. Europe’s 1980–2010 average of 8.4%
yields a UK to Europe ratio of 1:1.18.
Clinical output 1989–2010: UK Cancer Mortality Rates
was the sixth highest, but equal sixth biggest fall, signifi-
cantly greater than 14 other countries. UK Total
Mortality Rates was the fifth highest but third biggest
decline, significantly greater than 17 countries. UK’s
cancer Efficiency Ratios is largest at 1:301 and second big-
gest for Total Mortality Rates at 1.1341; the USA ratios
were 1:152 and 1:525, respectively.
Conclusions: UK reduced mortalities indicate that the
NHS achieves proportionally more with relatively less,
but UK needs to match European average Gross-
Domestic-Product-expenditure-on-Health to meet future
challenges.
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Introduction
The response to medical advances, greater expect-
ations, extended longevity and the rising cost of
health care, especially for cancer, means health inﬂa-
tion raises almost 3% p.a. and has meant that every
Western nation has the need to devote considerably
more of its ‘national income’, its gross domestic prod-
uct (GDP) to healthcare.1–6 This percentage of GDP
expended-on-health (GDPEH)5,6 raises the reason-
able question of how eﬃcient and eﬀective is the
UK and the other 20 Western countries in reducing
feasible mortality (adults 55–74). This needs to be
measured within the context of what each nation
spends of its GDP on health, irrespective of the
GDP cash value as it shows in proportional terms a
nation’s ﬁnancial commitment to healthcare. The
adult mortalities under consideration are cancer mor-
tality rates (CMR) and total mortality rates.
UK cancer services have received considerable
negative media coverage because the UK’s cancer
survival rates were much worse than many other
Western nations.7,8 However, using cancer survival
rates as an indicator ignores the serious methodo-
logical problems inherent in survival rates because
of diﬀerences in baseline measures9,10 due to a lack
of uniformity in the diﬀerent national cancer regis-
ters.11,12 Moreover, these earlier survival studies lar-
gely ignored the links between poorer outcomes and
socio-economic factors.13–16
A diﬀerent approach was taken in an earlier study
using conﬁrmed CMR between 1979 and 2006, as a
more reliable measure of outcome, to ﬁnd that over
the same period the UK had signiﬁcantly bigger
reductions in cancer deaths in people aged 55–7417
compared to countries whose survival rates were
apparently superior to the UK.7,8
The use of CMR as a measure of eﬀectiveness fol-
lows the British government’s cancer strategy for
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England that aimed to reduce cancer deaths for
people under 74,2,18 which is below the current UK
life expectancy of 79 years.19 Hence, the use of adult
(55–74) mortality rates as a measure of reducing
‘feasible’ mortality as it is lower than the current
UK life expectancy (WHO, 2015).
NewWHO data19 enable us to follow up the earlier
study17 and compare the latest available WHO mor-
tality data to determine whether the progress made by
the UK has continued. However, to avoid the criti-
cism that the earlier baseline, set then for 1979–1981,
is somewhat historical, the baseline years are more
recent and taken from 1989–1991 to 2008–2010.
Furthermore, to place CMR in a wider comparative
context, ‘total mortality rates’ (TMR) for adults (55–
74) are used as a control to see how the UK’s cancer
services have progressed in relation to overall adult
mortality. This allows a broader examination of the
nation’s response to the wider health matters not just
the high media attention given to cancer.
It is recognised that mortality rates are inﬂuenced
by many interactive clinical and policy issues, includ-
ing health and social policies, education, poverty, life-
style, inﬂuence of net migration, access to public
health, preventative as well as intervention health-
care.15,16,20–23 The extent of these diﬀerent factors
and their inﬂuence upon mortality outcomes would
need country-speciﬁc research. However, ﬁrst com-
paring a nation against itself over time provides a
reasonable degree of conformity and reliability of
clinical output.
Economic input is the percentage of GDPEH,
which is a measure of the ﬁscal priority each nation
gives to healthcare within its socio-economic
situation.
Of course, health expenditures are not just aimed
at reducing mortality but other objectives such
reducing chronic illness, etc. However, in the last
analysis, reducing mortality might be seen by the
public as the ‘ultimate’ health-care goal of every
nation’s health-care system, no matter how
structured.
There are two working null hypotheses. That over
the period there will be no statistically signiﬁcant dif-
ference between the UK and the other Westerns
countries in:
1. reducing both mortality rates, and
2. eﬃciency.
Method and design
To determine eﬃciency a nation’s ‘economic input’
to its healthcare is contrasted with its ‘clinical
outputs’, which is its comparative value added. It
is a truism that a nation can only have the services
it can aﬀord which raises the question of how do we
compare what diﬀerent nations aﬀord for health and
to what extent can we measure the relative and com-
parative priorities they devote to health? One meas-
ure is the percentage of the country’s national
income devoted to health expenditure, the percent-
age of GDPEH. This indicates the priority each
country aﬀords for its health services irrespective
of the conﬁguration of services or the cash value
of the GDP of each country. These GDP cash
values diﬀer enormously, for example between
Britain and Portugal, but the % GDPEH is a com-
parative indicator of the priority, within
each national budget, that a nation gives to its
healthcare.
Economic input
The % GDPEH is the combined total public and
private monies that each nation spent on healthcare.
This is both from ‘public funding’, i.e. from State and
Central governments, and ‘private’ which is mainly
insurance.5,6 This varies in the diﬀerent countries
but is the total GDPEH and includes all funding
sources.5,6
The GDPEH data come from the US Bureau of
Statistics5 and the World Bank6 for the period 1980–
2010 based upon 24 separately reported years.
However, GDPEH data were not available in
Greece for three years, Australia and Japan two
years, and Belgium, Denmark and Portugal one
year so their averages are based upon fewer years.
The GDPEH data are set against the years for
which we have clinical output: 1989–2010. The
GDPEH data fall into two periods, 1980–1997 and
1998–2010, for which averages are calculated, plus an
overall average for 1980–2010. The averages are used
in the eﬃciency ratios (ER) which are derived by
dividing the reduced mortalities by the average
GDPEH for 1980–2010. The larger the ratio the
more eﬃcient is a nation.
To place the UK % GDPEH in a wider context,
this will be contrasted against the Western European
average (excluding the UK) over the period. A UK to
European average ratio is calculated to determine the
extent to which European countries on average spend
proportionately more or less of their national income
than the UK.
Clinical outputs
Mortality data for adults (55–74) per million (pm) of
population for CMR and TMR are drawn from
2 Journal of the Royal Society of Medicine Open 0(0)
WHO data up to 2008–2010.19 The baseline years are
the average for 1989–1991 for the latest index three-
year average of 2008–2010 for both sexes. This is later
than an earlier study whose base years were 1979–
1981 that might be considered too historical, and an
earlier baseline would have favoured the UK, as pre-
viously, the UK had the highest CMR in the West,17
and it is comparatively easier to make bigger percent-
age reductions from higher baselines, before the law
of diminishing returns increasingly operates.24–26
Each country’s mortality rates baseline and index
years are measured, eﬀectively measuring a country
against itself, from which a percentage of change is
calculated. Canada and New Zealand have slightly
earlier index years of 2007–2009.
However, when comparing eﬃciency, there is the
problem of ‘diminishing returns’. Countries that ini-
tially had a higher mortality level potentially have a
greater opportunity to improve over time, whereas
for those with lower rates, it takes an increasingly
greater input to achieve a comparable outcome.24–26
Findings
Economic input % GDPEH
Table 1 presents the % GDP Expenditure on Health
of all the 21 Western countries. Baseline and current
years and average (1980–2010) rates are given and the
averages for the 1989–1997, 1998–2010 and 1980–
2010 periods. In addition, the levels of health expend-
iture are given for the years 2011–2013.
In 1980, the USA led GDPEH at 9% followed by
Denmark and Sweden with 8.9%, down to Portugal
and Spain at 5.3%. The UK was the third lowest at
5.6%. The 15 European countries’ average was 7.1%.
Over the period 1980–1997, the UK average
GDPEH was 6.2% and ranked 20th out of 21 coun-
tries. The European average was 7.7%, yielding a UK
to European ratio of 1:1.24.
From 1998 to 2010, USA expenditure rose from 14
to 17.1%, an average of 16.4%, followed by
Switzerland 10.8% and Germany 10.7%. The UK
went from 6.7% to 9.4% by 2010, averaging 7.9%,
ranked equal 17th. The European average was 9.1%
yielding a UK to Europe ratio of 1:1.15.
The highest overall average for the period 1980–
2010 was the USA at 13.2%, followed by Germany at
9.5% then France and Switzerland at 9.4%, down to
the UK at 7.1%, then Spain 7.2% and Ireland 7.3%.
The European average of 8.4% produced a UK to
Europe ratio of 1:1.18.
In eﬀect over the whole period, on average Europe
spent an equivalent 18% more of its national income
on health than did the UK, while Germany which is
famous for its ﬁnancial prudence averaged 9.8%, a
UK to German ratio of 1:1.38, while the comparison
with the USA yielded a UK to USA ratio of 1:1.86.
It is noted that while from 1980 the GDPEH had
risen considerably in all countries over the whole time
span, in some years the GDPEH fell compared to the
previous year’s expenditure. This occurred in the UK
in the years 1984, 1987, 1988, 1994, 1995, 2011 and
2013.
Clinical outputs
Cancer mortality rates 55–74 year olds (CMR). Table 2
shows the percentage of change in CMR between
1989–1991 and 2008–2010 ranked by the highest cur-
rent rate. Spain, at 6424 pm, had the highest rate, the
Netherlands 5761 pm and Portugal 5629 pm, who
with Spain were the only two countries to report
increases over the period, rises of 22% and 16%,
respectively. The lowest was Sweden at 3280 pm, a
fall of 38%. Australia was at 4055 pm, down 31%,
and Switzerland had a decline of 24%.
Over the period, the UK CMR fell in relation to
European average. In 1989–1991 there was a UK to
Europe ratio of 1:0.83; by 2008–2010 it was 1:0.88.
The UK had been second highest but now at
5146 pm was the sixth highest. The UK rate of
5146 pm is a 28% reduction and is the equal sixth
biggest fall of all countries.
Total mortality rates 55–74 year olds (TMR). Table 3
shows the highest current rate was Denmark at
13,333pm followed by the USA 12,605pm and
Germany 12,493pm to the lowest, Switzerland at
8317pm, Australia 8450pm and Spain 9295pm. Every
country had substantial falls over the period, from
Japan, an equivalent of 28%, to Ireland, a fall of 51%.
The UK had been the third highest but was now
ﬁfth at 11,570 pm, having the second biggest reduc-
tion at 44% over the period.
UK compared with 20 western countries
Table 4 shows the resulting conﬁdence intervals of
comparing each nation with the UK results for
CMR and TMR.
With respect to cancer deaths, the UK had statis-
tically bigger falls than 14 other nations, though
Sweden had signiﬁcantly better CMR outcomes
than the UK.
With regard to total mortality, the UK had signiﬁ-
cantly better reductions than 17 other Western
nations, including the USA. However, Ireland and
the Netherlands had signiﬁcantly better TMR results
than Britain.
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Efficiency ratios (ERs)
Table 5 shows that, in terms of ER for cancer deaths,
the UK was the most eﬃcient with a ratio of 1:301,
followed by Denmark 1:288 and Sweden 1:278. The
lowest ER was Greece 1:41, Germany 1:94 and Japan
at 1:98. The USA was ranked 13th with a ratio of
1:144, yielding a USA to UK ratio of 1:2.09. Europe
average cancer ER was 1:176, a Europe to UK ratio
of 1:1.71.
Total mortality
In terms of TMR, the best ER was Ireland at 1:1620,
followed by the UK at 1:1341, then New Zealand at
1:1122. The lowest was Japan at 1:307; France was at
Table 1. GDP Health Expenditure for 1980–2013 – based upon 24 years’ reporting unless noted (= denotes equal ranking).
Country and rank
(1) Missing years 1980 1997
Average
1980–97 1998 2010
Average
1998–2010
Overall average
1980–2010
Average
2011–2013
1. USA 9.0 13.9 9.9 14 17.1 16.4 13.2 17.1
2. Canada 7.0 9.3 9 9.3 11.1 9.8 9.7 10.9
3¼. Germany(1) 8.4 10.7 8.8 10.6 11.6 10.7 9.4 11.3
3¼. France 7.0 9.9 8.8 9.6 11.6 10.4 9.4 11.6
5. Switzerland 7.3 10.2 8.5 10.4 10.9 10.8 9.3 11.3
6. Sweden 8.9 8.6 8.6 7.9 9.5 8.8 8.6 9.6
7. Netherlands 7.4 8.5 8.3 8.7 12.1 9.4 8.5 12.6
8. Austria (2) 7.4 8.4 8 8.4 11.1 9.4 8.4 11.0
9. Belgium (1) 6.3 7.9 7.4 8.6 10.6 9.7 8.1 10.8
12¼. Italy 7.0 7.6 7.6 7.7 9.4 8.4 7.9 9.2
12¼. Norway 7.0 7.5 7.5 8.6 9.4 8.7 7.9 9.4
12¼New Zealand 5.9 7.6 7.1 8.6 10.0 8.6 7.9 10.0
12¼. Australia (2) 6.1 8.4 7.6 8.6 8.9 8.4 7.9 9.0
14. Finland 6.3 7.7 7.7 7.4 9.0 7.7 7.7 9.1
15. Denmark (3) 8.9 8.1 7.1 8.3 11.1 9.0 7.5 10.8
16. Portugal (1) 5.3 7.9 6.7 6.4 10.9 8.8 7.3 10.0
17. Ireland 8.2 7 7.3 6.9 9.2 7.3 7.1 8.8
19¼. Greece (3) 5.9 8.6 6.1 8.4 9.5 9.1 7 9.6
19¼. Spain 5.3 7.4 6.5 6.6 9.6 7.9 7 9.2
19¼. Japan (2) 6.5 7.2 6.7 7.5 9.6 8.0 7 10.2
21. UK 5.6 6.7 6.2 6.7 9.4 7.9 6.7 9.2
UK’s rank [4th] 19th 21st 20th 19th 17th¼ 18th¼ 18th¼ 18th
Europe average 7.1 8.4 7.7 8.3 10.4 9.1 8.3 10.3
UK: EU ratio 1.27 1.25 1.24 1.24 1.11 1.15 1.24 1.12
Note: Countries ranked by Average GDPHE 1980–2010.
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1:441 and Greece 1:467. The USA was 18th at 1:497,
a USA to UK ratio of 1:2.70.
An average Europe ER for total deaths was 778, a
Europe to UK ratio of 1:1.72.
From these results, it is reasonable to con-
clude that the UK, Ireland and Denmark are
the most eﬃcient in reducing adult (55–74)
cancer and total adult (55–74) mortality with
positive outcomes in regards to comparative
value added.
Discussion
Principal findings
The null hypothesis that there would be no signiﬁ-
cant diﬀerences between reduction in UK and
other countries’ mortality rates is rejected as the
UK had signiﬁcantly greater falls in cancer and
total death rates than 14 and 17 countries,
respectively.
Moreover, the hypothesis that there would be little
diﬀerence between the eﬃciency of the UK services
Table 2. Cancer mortality rates (CMR) 55–74 people 1989–1991 vs. 2008–2012 rates per million (UK highlighted in
Bold).
Country 1989–1991 vs. latest year.
CMR
1989–1991
CMR
2008–2010 % Change
1 (18) Spain 5284 6424 þ22
2 (5) Netherlands 6583 5761 12
3 (19) Portugal 4832 5629 þ16
4 (1) Denmark 7735 5577 28
5 (4) New Zealand 2007–2009 6721 5214 22
6 (2) UK 2008–2010 7161 5146 28
7 (12) Germany 1990–1992 5873 4986 15
8 (3) Ireland 6801 4911 28
9 (9) Belgium 6179 4861 21
10 (10) France 6103 4836 21
11 (8) Italy 6356 4804 24
12 (6) USA 6565 4664 29
13 (11) Austria 5992 4606 23
14 (7) Canada 2007–2009 6358 4520 29
15 (21) Greece 4677 4387 6
16 (14) Norway 5808 4385 24
17 (15) Finland 5399 4136 14
19 (20) Japan 4772 4083 14
18 (16) Switzerland 5350 4078 24
20 (13) Australia 5842 4055 31
21 (17) Sweden 5324 3280 38
Note: Ratio of change ranked by highest CMR.
Ranks of CMR Rho¼þ0.4467; p<0.05.
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and the other countries is rejected as the UK had the
best Eﬃciency Ratios for cancer and second greatest
ratio for Total Mortality, demonstrating positive
comparative value-added in the context of national
budgets devoted to health. Moreover, the UK ERs
were more than double those of the USA, whose
GDPEH exceeded that of every Western country.
Indeed, in terms of GDPEH and clinical outcomes,
while the UK was one of the most eﬀective, the USA
was the least eﬀective of the Western countries even
more so when extended to child mortality.27
Strengths and weakness
One limitation inherent in comparing international
mortality statistics is the possible variation in deter-
mining ‘primary causes of death’. With respect of
total mortality, there is no ambiguity as the rates
Table 3. All cause death rates (55–74) per million (pm) 1989–1991 vs. 2008–2010 and ratio of change % (UK high-
lighted in Bold).
Country current ranks and 1989–1991 rank 1989–1991 2008–2010 Change %
1 (6) Denmark 21,104 13,333 37
2 (4) USA 19,168 12,605 36
3 (6) Germany 1990–2010 18,230 12,493 31
4 (8) Portugal 17,902 11,734 34
5 (3) UK 20,554 11,570 44
6 (10) Austria 17,693 11,458 35
7 (9) Finland 17,845 11,451 36
8 (1) Ireland 22,358 10,853 51
9 (12) Belgium 16,874 10,844 36
10 (18) Greece 14,093 10,826 23
11 (11) Netherlands 16,938 10,647 37
12 (13) Canada 16,392 10,269 37
13 (17) France 14,299 10,154 29
14 (5) New Zealand 18,843 9982 47
15 (7) Norway 18,042 9955 35
16 (15) Italy 15,661 9796 37
17 (21) Japan 11,818 9669 28
18 (14) Sweden 16,297 9619 41
19 (16) Spain 14,625 9295 36
20 (20) Australia 12,394 8450 32
21 (19) Switzerland 13,589 8317 39
Averages 16,189 10,176 37
Note: TMR ranks 1989–2010 Rho ¼ þ0.7351 p<0.001.
Ranked by highest current rate.
CER cancer and public GDPEH Rho¼ þ0.6805; p<0.001.
CER TMR and public GDPEH Rho¼ þ0.5414; p<0.01.
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are total mortality. Cancer rates revolve around pri-
mary or secondary causes of death related to malig-
nancies but are unlikely to be an over-estimate.19
Crucially, the WHO data are the most consistent
available and by comparing a country against itself,
any vagaries of reporting diﬀerences between coun-
tries are lessened.19
Relations to other studies
In relation to UK cancer deaths, these results chal-
lenge the outcomes concerning cancer survival rates,
where every Western country has improved its sur-
vival rates, and the UK appeared less successful.
However, the reduction in Western cancer mortality
for the under 74s is in the same direction as the
survival rate data, but it would appear that cancer
mortality rates are a more reliable measure than sur-
vival rates, as there is less ambiguity about death
rates from common baselines.9,10,17 Furthermore,
these results conﬁrm the earlier study that the UK’s
cancer mortality outcomes continue to improve and
relatively more so than in most other Western
countries.17
Implications
While self-evidently a nation can only have a health-
care system it can aﬀord, this study shows that the
UK aﬀorded substantially less than many other coun-
tries, yet the NHS achieved more with proportionally
less. This should be a boost for patients, families and
Table 4. UK versus 20 Western countries for all cause deaths and cancer mortality rates Confidence Intervals (significance in bold).
Country
TMR
lower
TMR
odds ratio
TMR
upper
CMR
lower
CMR
odds ratio
CMR
upper
Australia 1:1.17 1:1.21 1:1.26 1:0.92 1:0.97 1:1.02
Austria 1:1.11 1:1.15 1:1.19 1:1.01 1:1.07 1:1.13
Belgium 1:1.1 1:1.14 1:1.18 1:1.04 1:1.09 1:1.15
Canada 1:1.08 1:1.11 1:1.15 1:0.94 1:0.99 1:1.04
Denmark 1:1.09 1:1.12 1:1.16 1:0.95 1:1 1:1.05
Finland 1:1.1 1:1.14 1:1.18 1:1.01 1:1.07 1:1.13
France 1:1.22 1:1.26 1:1.31 1:1.05 1:1.11 1:1.17
Germany 1:1.18 1:1.22 1:1.26 1:1.12 1:1.18 1:1.24
Greece 1:1.32 1:1.36 1:1.41 1:1.24 1:1.31 1:1.38
Ireland 1:0.83 1:0.86 1:0.89 1:0.95 1:1 1:1.06
Italy 1:1.07 1:1.11 1:1.15 1:10 1:1.05 1:1.11
Japan 1:1.4 1:1.45 1:1.51 1:1.13 1:1.19 1:1.26
New Zealand 1:1.08 1:1.12 1:1.15 1:1.16 1:1.22 1:1.28
Netherlands 1:0.91 1:0.94 1:0.97 1:1.03 1:1.08 1:1.14
Norway 1:0.95 1:0.98 1:1.01 1:1 1:1.05 1:1.11
Portugal 1:1.13 1:1.16 1:1.2 1:1.54 1:1.62 1:1.71
Spain 1:1.09 1:1.13 1:1.17 1:1.61 1:1.69 1:1.78
Sweden 1:1.01 1:1.05 1:1.08 1:0.81 1:0.86 1:0.91
Switzerland 1:1.05 1:1.09 1:1.13 1:10 1:1.06 1:1.12
USA 1:1.13 1:1.17 1:1.21 1:0.94 1:0.99 1:1.04
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front-line staﬀ. Moreover, the actual and relative suc-
cess of the NHS in achieving medicine’s pri-
mary objective, reducing death rates, should
reconﬁrm that the NHS model is both eﬀective and
eﬃcient.
When things go wrong, as outlined in the Francis
Report concerning an excess of deaths,28 the media
make great play of the NHS being inadequate.
However, there is seldom any discussion about the
adequacy of resources needed to meet clinical targets.
There are two key paragraphs in the Francis Report
related to resources, which merit consideration.
In para 1.16 page 16, Francis stated that ‘the
board . . .must bear some of the collective responsi-
bility for allowing the mismatch between the
resources allocated and the needs of the ser-
vice . . . to persist with protest or warning of the
consequences’.
In a later paragraph 1.46 Francis criticised the
Strategic Health Authority who ‘failed to alert those
responsible for the problem’ of the mismatch.28
In other words, the authorities failed to acknow-
ledge that the Trust did not have a feasible budget to
meet the needs of the service.
This poses the question, does the NHS have the
necessary feasible budget to meet the future chal-
lenges? Consider what could be achieved if the NHS
had the resources that matched the overall European
average. This would have meant a further 18% of
resources over the period, or an additional 15%
over the shorter term. This would go a long way to
reduce A&E waiting times and provide adequate
social care, reduce delayed discharges. If the UK
equalled the European average then like Germany
and France it might have operating theatres devot-
edly entirely to emergency care as in France and
Germany, avoiding disrupting elective surgical lists.
Matching the Western European average %
GDPEH is a worthy policy objective that the wider
public would see as fair, for when comparatively jud-
ging the NHS it becomes clear that the service is both
eﬀective and eﬃcient. Yet, over the last ﬁve years
(2010 to 2013), the World Bank6 showed that relative
to the nation’s wealth, the UK devoted proportion-
ately less of its GDP to health than previous years,
which undermines the NHS eﬀorts to respond to the
challenges of a still increasing cancer incidence, rising
cost of advanced medicine and longevity.1–6
We need to ask, what can and should Britain
aﬀord for health so that patients can continue to
receive the quality of care they require? Parity
with Western Europe would go a long way to achiev-
ing this.
Unanswered questions
The issue of why the discrepancies between the UK
survival rates and cancer mortality exist is unresolved
and probably requires country-speciﬁc research.
Nonetheless, both sets of data are showing
Table 5. UK and Western countries GDPEH cost-effective-
ness ratios (CEF) for cancer-mortality-rates and all cause
deaths 1989–2010.
Country
CMR–TMR ranks
Cancer
CEF 1
All cause
CEF 1
Combined
ranks
1–2 UK 301 1341 1.5
4–1 Ireland 266 1620 2.5
2–5 Denmark 288 1036 3.5
7–3 New Zealand 191 1122 5.0
4–8 Sweden 278 777 6.0
9–5 Norway 180 1024 7.0
6–11¼ Italy 196 742 8.8
11–7 Finland 164 830 9.0
10–11¼ Austria 165 742 10.5
8–14 Canada 189 625 11.0
12–10 Belgium 163 744 11.0
5–17 Australia 226 499 11.0
20¼ –6 Portugal Xx 845 13.3
20¼ 9 Spain Xx 761 14.8
17–13 Netherlands 97 740 15.0
13–18 USA 144 497 15.5
14¼16 Switzerland 135 567 15.5
18–15 Germany 94 610 16.5
14¼ –20 France 135 441 17.3
16–21 Japan 98 307 18.0
19–19 Greece 41 467 19.0
Europe average
Europe average: UK
176
1: 1.76
778
1: 1.72
–
Note: ranked by combined ranks.
CEF for CMR and TMR Rho¼ þ0.7144; p< 0.001.
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improvements and apart from Portugal and Spain,
whose rates rose, eﬀective treatment of cancer has
never been better and never more so in the United
Kingdom.
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